MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions

MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions

Abstract MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexifo...

Full description

Bibliographic Details
Main Author: Anja Harder
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Biomarker Research
Subjects:
MEK inhibitor
Neurofibromatosis
NF1
NF2
Schwannomatosis
LGG
Online Access:https://doi.org/10.1186/s40364-021-00281-0

Internet

https://doi.org/10.1186/s40364-021-00281-0

Similar Items